Literature DB >> 12145812

Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis.

Lee A Denson1, Alan Bohan, Matthew A Held, James L Boyer.   

Abstract

BACKGROUND & AIMS: Obstructive cholestasis is associated with adaptive changes in expression of hepatocyte transport proteins. These include a significant reduction in hepatic expression of Mrp2 (Abcc2), the principal canalicular multispecific organic anion transporter. Renal Mrp2 expression is preserved under these conditions. We have recently reported that the rat Mrp2 promoter is activated by RAR alpha:RXR alpha, and that interleukin 1 beta (IL-1 beta) repressed promoter activity via this element. We hypothesized that cytokines, which are up-regulated in obstructive cholestasis, would reduce nuclear RAR alpha:RXR alpha levels, and that this would be associated with suppression of hepatic Mrp2 expression.
METHODS: Male Sprague-Dawley rats were subjected to bile duct ligation (BDL) or sham surgery, and liver and kidney RNA and protein were isolated. Primary rat hepatocytes were treated with bile acids, retinoids, or cytokines, and RNA and protein were isolated. Mrp2 and RAR alpha:RXR alpha protein abundance and activity were assessed by using electrophoretic mobility shift assays (EMSA) and immunoblots. IL-1 beta abundance was determined by enzyme-linked immunosorbent assay. RAR alpha, RXR alpha, and Mrp2 RNA levels were determined by using ribonuclease protection assays (RPA).
RESULTS: Mrp2 down-regulation and IL-1 beta up-regulation were observed in liver after BDL. This was temporally associated with down-regulation of liver RAR alpha:RXR alpha nuclear protein levels and binding to the Mrp2 promoter cis element. Renal RAR alpha:RXR alpha and Mrp2 expression were preserved under these conditions. IL-1 beta treatment of primary hepatocytes reduced Mrp2 and RXR alpha expression.
CONCLUSIONS: Organ-specific regulation of Mrp2 expression in obstructive cholestasis is associated with cytokine-dependent alterations in RAR alpha:RXR alpha nuclear receptors. Preservation of renal Mrp2 expression may permit urinary excretion of toxic organic anions and xenobiotics under conditions in which biliary excretion is impaired.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145812     DOI: 10.1053/gast.2002.34758

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells.

Authors:  Tiangang Li; Asmeen Jahan; John Y L Chiang
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

2.  Renal elimination of organic anions in cholestasis.

Authors:  Adriana Monica Torres
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

3.  Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression.

Authors:  Wensheng Chen; Shi-Ying Cai; Shuhua Xu; Lee A Denson; Carol J Soroka; James L Boyer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-02-01       Impact factor: 4.052

Review 4.  Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.

Authors:  Gustav Paumgartner
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 5.  Expression and function of renal and hepatic organic anion transporters in extrahepatic cholestasis.

Authors:  Anabel Brandoni; María Herminia Hazelhoff; Romina Paula Bulacio; Adriana Mónica Torres
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

6.  Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses.

Authors:  Qiao-Ling Yang; Fan Yang; Jun-Ting Gong; Xiao-Wen Tang; Guang-Yun Wang; Zheng-Tao Wang; Li Yang
Journal:  Acta Pharmacol Sin       Date:  2016-08-08       Impact factor: 6.150

7.  Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids.

Authors:  Lirui Wang; Phillipp Hartmann; Michael Haimerl; Sai P Bathena; Christopher Sjöwall; Sven Almer; Yazen Alnouti; Alan F Hofmann; Bernd Schnabl
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

8.  The traditional ayurvedic medicine, Eugenia jambolana (Jamun fruit), decreases liver inflammation, injury and fibrosis during cholestasis.

Authors:  Ajay C Donepudi; Lauren M Aleksunes; Maureen V Driscoll; Navindra P Seeram; Angela L Slitt
Journal:  Liver Int       Date:  2011-12-30       Impact factor: 5.828

Review 9.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 10.  ABC of oral bioavailability: transporters as gatekeepers in the gut.

Authors:  C G Dietrich; A Geier; R P J Oude Elferink
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.